20 articles
Anthropic established a physical biology lab to advance AI-driven drug discovery, partnering with major pharma firms like Novartis and Roche. The company acquired Coefficient Bio to accelerate develop
Novartis shares dropped 11% following a late-stage trial failure for drug del-desiran, sparking investor concerns over its M&A strategy and $12 billion Avidity acquisition amid patent expiry challenge
Artisan Partners urges Novartis board changes after failed drug trials wiped nearly $30 billion from its market value. The shareholder criticizes the company's M&A strategy and compensation structure,
European shares declined as rising crude oil prices fueled inflation fears, while Novartis stock tumbled following two failed late-stage drug trials. Meanwhile, Sandoz gained ground on ambitious sales
Novartis shares fell nearly 9% after a failed late-stage trial for its muscle-wasting disorder drug, the second major pipeline setback this year. The failure pressures CEO Vas Narasimhan's acquisition
European markets declined amid inflation fears from rising oil prices linked to U.S.-Iran tensions. Novartis shares fell after its experimental drug pelacarsen missed a key late-stage trial goal.
Novartis shares fell 3.3% after its cholesterol drug pelacarsen failed a late-stage study targeting high Lp(a) levels. This setback increases pressure on the company's gene therapy pipeline and impact
Novartis plans to relocate laboratory and biologics production activities from its Kleinbasel site to its main campus, potentially cutting around 130 jobs by 2028. The move aligns with lease expiratio
Thirteen new clinical drug candidates targeting diseases such as cancer and obesity were disclosed at the American Chemical Society Fall 2026 meeting, highlighting efforts from major pharmaceutical co
Swiss GDP grew 1.5% in Q2, surpassing forecasts and driven by pharmaceuticals and chemicals. Pharma giants Novartis and Roche posted earnings beats, reinforcing the sector's contribution to national e
Novartis reported a second-quarter profit beat and maintained its 2026 outlook despite facing patent cliffs on key drug Entresto. The company highlighted upcoming trial results for three experimental
Oil prices drive global markets amid Middle East tensions, boosting Asian chips despite inflation fears, while Novartis and Julius Baer earnings loom.
Novartis investors await critical second-half drug trial readouts for key candidates to justify its premium valuation against looming patent expiries. Analysts warn failures could significantly impact
Novartis agreed to acquire UK biotech Myricx Bio for up to $1.5 billion to expand its antibody-drug conjugate cancer treatments, with the deal set to close in the second half of 2026.
Fuller plans to acquire wound-care company AMS, while Novartis and Antares agree on cancer small molecules; the report notes hardware stores remain key outlets for chemical products despite retail con
The U.S. may launch a Section 301 trade investigation into Switzerland's pharmaceutical sector over potential price cuts, mirroring actions against Germany. Industry leaders warn this could impact maj
Roche and Novartis warn a proposed Swiss population cap threatens skilled talent access, risking R&D capabilities in Basel. Industry leaders argue this undermines Switzerland's status as a global phar
Swiss companies invested $27 billion in the U.S. between January and April following a tariff agreement reducing duties on Swiss goods. Major pharmaceutical firms Novartis and Roche announced new faci
Swiss drugmaker Novartis plans to shut down its Wehr production site by late 2028, eliminating around 220 jobs. The facility produced tablets and capsules but was deemed uncompetitive.
Pharmaceutical services firms unveiled major manufacturing expansions at DCAT Week, including Cambrex's $130 million API project in Iowa and BSP Pharmaceuticals' $800 million investment in antibody-dr
ChemBrief